Notes

The fund, called Catalyst, is for research on IONS, MIRM, GIS, EAT, and CAG, with a size of 0, as of September 26, 2026, at 11:01:10 UTC. There are SEC filings for IONS on September 23, MIRM on September 8, GIS on September 23, and EAT on September 17. On September 25, the FDA approved Atebrioz for a specific medical condition. GIS had a conference on September 8, which is already past, and a morning earnings report on September 23. The earnings report had a Q&A session at 13 UTC, but the exact release time is unknown. For GIS, stronger organic cash flow and guidance will be recorded and validated, while weaker or absent results will require re-verification of cash flow. There will be no automatic entry, and the dates listed are for review, not first news. The baseline for July 1, FY27, is an EPS of 3.00-3.20, with organic growth of -1.5 to +0.5%, and savings of 750 million. EAT had an investor day on August 31, and an earnings call is scheduled for October 28, with a review at 16:30 UTC. For EAT, stronger organic cash flow will be recorded and independently validated, while weaker or absent results will require re-verification of cash flow. The fund has a research-only status, with no orders, and is set to UTC time.

The Catalyst fund is currently in research mode only, with a size of 0, as of September 26, 2026, at 07:01:10 UTC. The fund is tracking the following stocks: IONS, MIRM, GIS, EAT, and CAG. The fund manager has reviewed SEC filings for IONS on September 23, 2026, MIRM on September 8, 2026, GIS on September 23, 2026, and EAT on September 17, 2026. On September 25, 2026, the FDA approved Atebrioz for Fibrodysplasia Ossificans Progressiva in adults and pediatric patients. GIS had a conference on September 8, 2026, at 19:40 UTC, which has already passed. The fund manager will review the replay. On September 23, 2026, GIS released its morning earnings at 13:00 UTC, with a Q&A session. The fund manager will review the earnings release. If GIS has stronger organic cash flow and guidance, the fund manager will record and validate the results. If the results are weaker or absent, the fund manager will reverify the cash flow. The fund manager will not make any automatic entries. The baseline for GIS is a fiscal year 2027 EPS of $3.00-3.20, with organic growth of -1.5% to +0.5%, and savings of $750 million. The fund manager has also reviewed EAT's investor day on September 17, 2026, and its earnings call date on October 28, 2026. The fund manager will review EAT's earnings release on October 28, 2026, at 16:30 UTC. If EAT has stronger organic cash flow, the fund manager will record and validate the results. If the results are weaker or absent, the fund manager will reverify the cash flow. The fund manager will not make any automatic trades. The fund is currently in research mode only, with no orders.

A fund manager's notes were compiled on 2026-09-26T05:46:06.058900+00:00. The fund is called Catalyst Research, and it has a size of 0. The notes include compact receipts and originate from the PRE91108 archive. The notes are divided into 11 panels, each with a unique sha code, which is a type of digital fingerprint. The panels contain previews of various events and announcements, including SEC filings for HITI and BFRI, earnings reports for Dave & Buster's, and conference announcements for EGTX. One panel mentions an ITC, which stands for International Trade Commission, and a lifted suspension. The previews are not guaranteed to be up-to-date or accurate, and readers are advised to read the originals before taking action.

The Catalyst fund is currently in research mode only for the stocks IONS, MIRM, GIS, and EAT, with a size of 0. As of September 26, 2026, at 03:01:09 UTC, the fund has the following notes: IONS had an SEC filing on September 23, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/874015/000114036126037371/ef20082626_8k.htm. MIRM had an SEC filing on September 8, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/1759425/000175942526000047/mirm-20260902.htm. GIS had an SEC filing on September 23, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/40704/000162828026063141/gis-20260923.htm. EAT had an SEC filing on September 17, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/703351/000070335126000032/eat-20260917.htm. On September 25, 2026, the FDA approved Atebrioz for Fibrodysplasia Ossificans Progressiva in adults and pediatric patients. GIS had a conference on September 8, 2026, at 19:40 UTC, which is already past, and a replay is available. On September 23, 2026, GIS released its earnings, with a Q&A session at 13:00 UTC, and the first release time is unknown. The fund has a baseline for GIS, with an expected EPS of 3.00-3.20 for FY27, and organic growth of -1.5 to +0.5%. The fund also has a baseline for EAT, with an investor day on August 31, 2026, and an earnings call on October 28, 2026. The fund will review these stocks on the specified dates, but will not make any automatic trades. The fund will verify the full pipelines and early news for these stocks.

The Catalyst fund is currently in research mode only, with no active orders, and is focused on the stocks IONS, MIRM, GIS, and EAT, as well as CAG. The fund size is 0 and the current time is 2026-09-25T23:00:19.281986+00:00 UTC. The fund manager has reviewed recent SEC filings for IONS, MIRM, GIS, and EAT, which were published on 2026-09-23, 2026-09-08, 2026-09-23, and 2026-09-17, respectively. A news scan found the headline 'FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients' on 2026-09-25T18:53:48Z. The GIS company had a conference on September 8 at 19UTC, which has already passed, and the fund manager plans to review the replay. On September 23, GIS released its morning earnings at 13UTC, but the exact time of the first release is unknown. The fund manager will review the earnings and verify the cash flow, with a stronger organic cash flow leading to recording and validation, and a weaker or absent cash flow leading to re-verification. The baseline for GIS is an EPS of 3.00-3.20 for FY27, with an organic growth of -1.5 to +0.5% and savings of 750m. The EAT company had an investor day on August 31, and the fund manager plans to review it on September 17 at 16:30UTC. The EAT company also announced its earnings call date for October 28, but the exact time is unknown. The fund manager will review the earnings and verify the cash flow, with a stronger organic cash flow leading to recording and validation, and a weaker or absent cash flow leading to re-verification. The fund manager will verify the full pipelines and early news for all stocks.

The fund is called Catalyst Research and it has a size of 0. It is compacting receipts and the origins are in the PRE91108 archive. This was done on 2026-09-25T21:45:32.486523+00:00. There are 11 panels of information. Panel 0 has 70 characters and a sha, or secure hash algorithm, of debc66f45e572825. Panel 1 has 101 characters and a link to the SEC, or Securities and Exchange Commission, website for HITI from 2026-09-23. Panel 2 has 98 characters and a link to the SEC website for BFRI from 2026-09-14. Panel 3 has 216 characters and a preview of Dave & Buster's second quarter 2026 report from September 14, 2026. Panel 4 has 246 characters and mentions TSM and DATA.L S, with a note that reviews are chosen but not guaranteed for release or delivery. Panel 5 has 260 characters and mentions CAN and PLAY with specific dates and times. Panel 6 has 353 characters and mentions improved organic cash and credible clinical evidence. Panel 7 has 160 characters and mentions EGTX with a count of 48 and a hash of 85e339a790c3. Panel 8 has 206 characters and mentions EGTX chosen reviews with specific dates and times. Panel 9 has 99 characters and a link to the USITC, or United States International Trade Commission, website for BFRI. Panel 10 has 341 characters and mentions BFRI with a link to the federal register website. The raw sha is a10d718d6511a29c144fc778c3ec8c742953e0e8996019761e08f6eac32b3fcc.

The Catalyst fund is currently researching IONS, MIRM, GIS, and EAT, with no active orders. As of September 25, 2026, at 18:45:31 UTC, the fund size is 0. The fund manager has reviewed SEC filings for IONS on September 23, MIRM on September 8, GIS on September 23, and EAT on September 17. On September 24, HC Wainwright & Co reiterated a buy rating on Ionis Pharmaceuticals with a $100 price target. GIS had a conference and review on September 8, and the fund manager notes that it is already past, but a replay is available. The fund manager also notes that GIS had morning earnings on September 23, with a Q&A session at 13 UTC, but the first release time is unknown. The fund manager has set a baseline for GIS's fiscal year 2027, with expected EPS of $3.00-3.20, organic growth of -1.5% to +0.5%, and savings of $750 million. The fund manager has also reviewed EAT's investor day on September 17 and notes that the company will have an earnings call on October 28, with a review scheduled for 16:30 UTC. The fund manager has set criteria for evaluating GIS and EAT, including stronger organic cash flow and weaker or absent cash flow, but notes that there will be no automatic entry or trade. The fund manager will verify full pipelines and early news for GIS and EAT. As of September 25, 2026, at 18:45:37 UTC, the fund is still in research mode only, with no orders.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 25, 2026, at 17:35:57 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, LOVE on September 10, 2026, and SFIX on September 23, 2026. A SEC filing is a report that a company submits to the Securities and Exchange Commission. The manager also reviewed the following RSS feeds: SAIL on September 22, 2026, KFY on September 9, 2026, and LOVE on September 24, 2026. An RSS feed is a way for companies to share news and updates. Additionally, the manager reviewed an FDA update on GRAL, which is a meeting of the Molecular and Clinical Genetics Panel, a group that advises on medical devices. The FDA, or Food and Drug Administration, is a government agency that regulates medical devices and drugs. The manager noted that the SEC filings may not be up to date with the latest news. The manager reviewed the following specific times: September 9 at 12:30 for new morning results, September 10 at 12:30 for LOVE, and September 24 at 12:30 for SFIX after the market closed on September 23. The manager also noted that the GRAL panel on September 23 was not an approval. The manager made decisions based on strong cash positions, which were validated, and weak or early positions, which were reverified. No automatic orders were placed.

The fund is called Catalyst Research and it is for research only. The fund size is 0 and the time is 2026-09-25T15:15:19.688438+00:00. There are several news updates: TLX on Sunday, September 20, 2026, announced a partnership with ITM, which can be found at https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/. AVO on Tuesday, September 8, 2026, announced its fiscal 2026 third-quarter financial results, which can be found at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial. ABM on Thursday, September 24, 2026, announced that it won the 2026 Gartner Marketing and Communications Award for Brand, which can be found at https://abm.gcs-web.com/news-releases/news-release-details/abm-wins-2026-gartner-marketing-and-communications-award-brand. ROIV on Wednesday, September 23, 2026, announced topline results for its proof of concept study IMVT-1402, which can be found at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-topline-results-proof-concept-study-imvt-1402. There are also several financial filings: UNFI filed its 10-K on September 14, 2026, DRI filed its 8-K on September 24, 2026, PPIH filed its 10-Q on September 9, 2026, MRK filed its 10-Q on August 7, 2026, and WLTH filed its 10-Q on September 14, 2026. Additionally, EPM announced that it will participate in upcoming investor conferences on Monday, September 21, 2026, which can be found at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-participate-upcoming-investor-conferences. IPHA filed its 6-K on September 17, 2026. The HTTP requests for KGF, ASKUL, IPHAnews, and SOBI were successful. The research is strong for new information and weak or absent for existing information. The decision is to read the originals and validate the information, and to cash and reverify weak or absent information. IPHA has a condition for Sobi receipt and Q1-2028. The monitors for 165, 168, 167, and 137, and 22 are preserved. There are no orders and the sources and dates can be found in the job script and journal.

The fund, called Catalyst, is for research only on the stocks IONS, MIRM, GIS, and EAT, as well as CAG, with a size of 0. The current time is 2026-09-25T14:30:24.851106+00:00 UTC. There are SEC filings for IONS on 2026-09-23, MIRM on 2026-09-08, GIS on 2026-09-23, and EAT on 2026-09-17. A discovery was made on 2026-09-24T10:59:30Z by HC Wainwright & Co, which reiterated a buy on Ionis Pharmaceuticals with a $100 price target. GIS had a conference on September 8 at 19UTC, which is already past, and a morning earnings report on September 23 at 13UTC. The baseline for GIS is an EPS of $3.00-3.20 for FY27, with organic growth of -1.5 to +0.5% and savings of $750m. EAT had an investor day on August 31 and will have an earnings call on October 28. The fund has specific rules for trading, including verifying full pipelines and early news, and does not allow automatic trades. The current status is research only, with no orders, as of 2026-09-25T14:30:31 UTC.

A fund manager reviewed notes from the Catalyst research fund, which has a size of 0 and compact receipts. The origins of the notes are in the PRE91108 archive, and the review took place on 2026-09-25T13:30:40.539202+00:00. The manager looked at various panels, including one about HITI SEC from 2026-09-23, another about BFRI SEC from 2026-09-14, and a news article about Dave & Buster's second quarter 2026 report from September 14, 2026. The manager also reviewed panels about TSM, DATA.L, CAN, and EGTX, including a conference schedule for EGTX. One panel reported a BFRI ITC error, and another noted that BFRI's ITC suspension was lifted on September 1, 2026. The review consisted of 11 panels, and the manager was advised to read the originals before taking action.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 25, 2026, at 13:30:21 UTC. The fund manager reviewed the following SEC filings: CHWY's 10-Q filing on September 9, 2026, ASO's 10-Q filing on September 9, 2026, LOVE's 10-Q filing on September 10, 2026, and SFIX's 8-K filing on September 23, 2026. The manager also reviewed the following RSS feeds: SAIL's announcement on September 22, 2026, KFY's press release on September 9, 2026, and LOVE's press release on September 24, 2026. Additionally, the manager checked the FDA website for updates on GRAL, which had a panel meeting on September 23, 2026, but this was not an approval meeting. The manager noted that the SEC filings may lag behind news and reviewed the following schedules: new morning results on September 9 at 12:30, LOVE's results on September 10 at 12:30, and SFIX's results on September 24 at 12:30 after the September 23 AMC. The manager also noted that strong cash positions should be recorded and validated, while weak or early cash positions should be cashed and reverified. No automatic orders were made.

The fund is called Catalyst Research and it is for research only. The size of the fund is 0 and the time is September 25, 2026, at 11:01:41 UTC. There are several news updates from various companies, including Telix Pharma on September 20, 2026, Mission Produce on September 8, 2026, ABM on September 24, 2026, Roivant on September 23, 2026, and Evolution Petroleum on September 21, 2026. Additionally, there are financial reports from UNFI on September 14, 2026, DRI on September 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 14, 2026. There are also HTTP status updates for KGF, ASKUL, IPHAnews, and SOBI. The research notes end with the instruction to preserve certain monitors and not to place any orders. A decision was made to replace 169 with an exit code of 0.

The Catalyst fund is currently in research mode only, with a size of 0, as of September 25, 2026, at 10:15:32 UTC. The fund is monitoring the following stocks: IONS, MIRM, GIS, EAT, and CAG. The fund manager has reviewed SEC filings for IONS on September 23, MIRM on September 8, GIS on September 23, and EAT on September 17. A discovery was made on September 24, where HC Wainwright & Co reiterated a buy rating on Ionis Pharmaceuticals with a price target of $100. GIS had a conference on September 8, which has already passed, and the fund manager will review the replay. On September 23, GIS released its morning earnings, and the fund manager will review the Q&A session. The fund manager has set a baseline for GIS's fiscal year 2027, with an expected EPS of $3.00-3.20 and organic growth of -1.5% to +0.5%. The fund manager is also monitoring EAT's investor day on September 17 and its upcoming earnings call on October 28. The fund manager has set rules for recording and verifying GIS and EAT's organic cash growth, but will not make any automatic trades. The fund manager will review the full pipelines and early news for these stocks.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 25, 2026, at 09:15:29 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, LOVE on September 10, 2026, and SFIX on September 23, 2026. The manager also reviewed the following RSS feeds: SAIL on September 22, 2026, KFY on September 9, 2026, and LOVE on September 24, 2026. Additionally, the manager checked the FDA website for updates on GRAL, which had a panel meeting on September 23, 2026, but this was not an approval. The manager noted that the SEC filings may lag behind news and reviewed the following schedules: new morning results on September 9 at 12:30, LOVE on September 10 at 12:30, and SFIX on September 24 at 12:30 after the September 23 AMC. The manager decided to preserve 80 and exit 0, with no automatic orders, and will review cash positions, validating strong cash and reverifying weak or early cash.

The fund is called Catalyst Research and it is for research only. The size of the fund is 0 and the time is 2026-09-25T07:00:23.798477+00:00 UTC. There are several news updates from various companies, including TLX on Sunday, September 20, 2026, which can be found at https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/, AVO on Tuesday, September 8, 2026, which can be found at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial, ABM on Thursday, September 24, 2026, which can be found at https://abm.gcs-web.com/news-releases/news-release-details/abm-wins-2026-gartner-marketing-and-communications-award-brand, ROIV on Wednesday, September 23, 2026, which can be found at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-topline-results-proof-concept-study-imvt-1402, UNFI on September 14, 2026, which filed a 10-K report, DRI on September 24, 2026, which filed an 8-K report, PPIH on September 9, 2026, which filed a 10-Q report, MRK on August 7, 2026, which filed a 10-Q report, WLTH on September 14, 2026, which filed a 10-Q report, EPM on Monday, September 21, 2026, which can be found at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-participate-upcoming-investor-conferences, and IPHA on September 17, 2026, which filed a 6-K report. There are also HTTP200 hash results for KGF, ASKUL, IPHAnews, and SOBI. The decision is to preserve monitors 165, 168, 167, 137, and 22, and there are no orders. The research is strong for new information and weak for absent or error information, and the originals should be read and validated. IPHA has a conditional receipt for Q1-2028.

The Catalyst fund is for research only on IONS, MIRM, GIS, and EAT, with no current size, as of September 25, 2026, at 06:15:21 UTC. The fund manager reviewed SEC filings for IONS on September 23, MIRM on September 8, GIS on September 23, and EAT on September 17. A discovery on September 24 from HC Wainwright & Co reiterated a buy rating on Ionis Pharmaceuticals with a $100 price target. GIS had a conference on September 8, which is past, and a morning earnings call on September 23. The fund manager will review GIS's stronger organic cash flow and guidance, and weaker or absent results will require re-verification. No automatic entry is allowed, and dates are for review, not first news. The baseline for GIS is a fiscal year 2027 EPS of $3.00-3.20, with organic growth of -1.5% to +0.5%, and savings of $750 million. EAT had an investor day on September 17 and an earnings call scheduled for October 28. The fund manager will review EAT's stronger organic cash flow and guidance, and weaker or absent results will require re-verification. The fund is set for research only, with no orders, as of September 25, 2026, at 06:15:28 UTC.

The fund is called Catalyst Research and its size is 0. It is compacting receipts and the origins of the data are in the PRE91108 archive. The current time is 2026-09-25T05:15:37.990953+00:00. There are 11 panels of data, which include information about various companies such as HITI, BFRI, and EGTX, as well as news and updates from the SEC and other sources. The panels contain previews of the data, including links to SEC filings and news articles. The data also includes information about upcoming events, such as conferences and earnings calls. A news scan found the headline 'Dave & Buster’s Reports Second Quarter 2026' on September 14, 2026. Another news scan found the headline 'EGTX chosen reviews' on September 11 and 16, 2026. The International Trade Commission, or ITC, lifted a suspension on BFRI on September 1, 2026. The data is not guaranteed to be up-to-date or accurate, and it is recommended to read the original sources before taking any action.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 25, 2026, at 05:15:27 UTC. The fund reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, LOVE on September 10, 2026, and SFIX on September 23, 2026. A SEC filing is a report that a company submits to the Securities and Exchange Commission. The fund also reviewed the following RSS feeds: SAIL on September 22, 2026, KFY on September 9, 2026, and LOVE on September 24, 2026. An RSS feed is a way for companies to share news and updates. Additionally, the fund reviewed an FDA update on GRAL, which is a company that has a meeting with the FDA, a government agency that regulates food and drugs, on September 23, 2026. The fund made the following decisions: exit 0, which means to close a trade, and preserves 80, which means to keep 80% of the fund's value. The fund will review the following dates: September 9 at 12:30 for new morning results, September 10 at 12:30 for LOVE, and September 24 at 12:30 for SFIX. The fund will also review GRAL's panel on September 23, but this is not an approval, which means it is not a final decision. The fund has strong cash, which means it has a lot of money, and will record and validate this. If the cash is weak, early, or absent, the fund will cash and reverify, which means it will check again. The fund will not make any automatic orders.

The fund is called Catalyst Research and it is for research only. The size of the fund is 0 and the time is 2026-09-25T02:45:25.378255+00:00 UTC. There are several news updates: TLX on Sunday, September 20, 2026, announced a partnership at https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/. AVO announced fiscal 2026 third-quarter financial results on Tuesday, September 8, 2026, at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial. ABM won a 2026 Gartner Marketing and Communications Award on Thursday, September 24, 2026, at https://abm.gcs-web.com/news-releases/news-release-details/abm-wins-2026-gartner-marketing-and-communications-award-brand. ROIV announced topline results of a proof-of-concept study on Wednesday, September 23, 2026, at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-topline-results-proof-concept-study-imvt-1402. There are also several financial filings: UNFI filed a 10-K on September 14, 2026, DRI filed an 8-K on September 24, 2026, PPIH filed a 10-Q on September 9, 2026, MRK filed a 10-Q on August 7, 2026, and WLTH filed a 10-Q on September 14, 2026. EPM will participate in upcoming investor conferences, announced on Monday, September 21, 2026, at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-participate-upcoming-investor-conferences. IPHA filed a 6-K on September 17, 2026. The HTTP status is 200 for KGF with a hash of 063338c90b2df309, ASKUL with a hash of e6f0d85c03a37ce6, IPHAnews with a hash of ef3293fd5ff26cb3, and SOBI with a hash of 9c07c8709019d6c1. The research is to read originals and validate strong and new information, and to cash and reverify weak, absent, or error information. IPHA has a condition on September 17 and Sobi has a receipt conditional on Q1-2028. The monitors 165, 168, 167, 137, and 22 are to be preserved. There are no orders and the sources and dates are in the job script and journal.

The fund, called Catalyst, is currently researching the stocks IONS, MIRM, GIS, and EAT, as well as CAG, with a size of 0. The fund's status was updated on September 25, 2026, at 02:15:19 UTC. The fund manager has been reviewing SEC filings for these stocks, including IONS on September 23, MIRM on September 8, GIS on September 23, and EAT on September 17. A discovery was made on September 24, where HC Wainwright & Co reiterated a buy rating on Ionis Pharmaceuticals with a price target of $100. The GIS stock had a conference on September 8, and the fund manager is waiting for a replay. The fund manager is also reviewing earnings reports, including GIS's report on September 23, and EAT's investor day on September 17. The baseline for GIS's earnings per share is $3.00-3.20, with organic growth expected to be between -1.5% and +0.5%. The fund manager has chosen to review EAT's earnings call on October 28, and will verify the first news release. The fund is currently in research mode only, with no orders, as of September 25, 2026, at 02:15:24 UTC.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 25, 2026, at 01:15:26 UTC. The fund manager reviewed the following SEC filings: CHWY's 10-Q filing on September 9, 2026, ASO's 10-Q filing on September 9, 2026, LOVE's 10-Q filing on September 10, 2026, and SFIX's 8-K filing on September 23, 2026. The manager also reviewed the following RSS feeds: SAIL's announcement on September 22, 2026, KFY's press release on September 9, 2026, and LOVE's press release on September 24, 2026. Additionally, the manager checked the FDA website for updates on GRAL, which had a panel meeting on September 23, 2026. The manager noted that SEC filings may lag behind news and reviewed the following schedules: new morning results on September 9 at 12:30, LOVE's results on September 10 at 12:30, and SFIX's results on September 24 at 12:30 after the September 23 AMC. The manager also noted that GRAL's panel meeting on September 23 was not an approval. The manager made decisions based on strong cash positions, which were recorded and validated, and weak or early positions, which were cashed and reverified. No automatic orders were placed.

The Catalyst research fund has a size of 0 as of September 24, 2026, at 22:45:17 UTC. The fund manager reviewed the following news and filings: TLX on September 20, 2026, about a partnership with ITM, a radiopharmaceutical company; AVO on September 8, 2026, about its fiscal 2026 third-quarter financial results; ABM on September 24, 2026, about winning a 2026 Gartner Marketing and Communications Award; ROIV on September 23, 2026, about topline results from a proof-of-concept study for IMVT-1402. The manager also reviewed filings from UNFI on September 14, 2026, DRI on September 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, WLTH on September 14, 2026, EPM on September 21, 2026, and IPHA on September 17, 2026. The manager checked the status of several websites, including KGF, ASKUL, IPHAnews, and SOBI, and found they were accessible, with specific hash values. The manager decided to preserve monitors 165, 168, 167, 137, and 22, and to take no orders. The manager will reverify weak or absent information and validate strong and new information by reading the originals.

The Catalyst fund is currently researching IONS, MIRM, GIS, and EAT, with no active positions, as of September 24, 2026, at 22:00:21 UTC. The fund has reviewed SEC filings for IONS on September 23, MIRM on September 8, GIS on September 23, and EAT on September 17. A discovery note from HC Wainwright & Co on September 24 reiterated a buy rating for Ionis Pharmaceuticals with a $100 price target. GIS had a conference on September 8, which has already passed, and will release earnings on a future date, with a review scheduled for 19:40 UTC. The fund is monitoring GIS's organic cash growth and guidance, with a baseline expectation of $3.00-3.20 EPS for FY27 and organic growth of -1.5% to +0.5%. EAT had an investor day on August 31, with a review scheduled for September 17, and will release earnings on October 28, with a review scheduled for 16:30 UTC. The fund is monitoring EAT's organic cash growth, with a threshold of -19.2065% for independent validation. The fund has ended its review of four SEC filings, one discovery note, two GIS events, and two EAT events, and will verify full pipelines and early news.

The fund is called Catalyst Research and it has a size of 0. The receipts are compact and the origins are in the PRE91108 archive. The current time is 2026-09-24T21:15:23.985468+00:00. There are 11 panels with different information. Panel 0 has a preview of the fund and its size. Panel 1 has a link to the SEC archives for HITI on 2026-09-23. Panel 2 has a link to the SEC archives for BFRI on 2026-09-14. Panel 3 has a news headline about Dave & Buster's reporting their second quarter 2026 results. Panel 4 mentions a chosen review of TSM on September 10. Panel 5 mentions a new review of CAN on September 8 and PLAY on September 15. Panel 6 talks about improved organic cash and credible clinical evidence. Panel 7 has information about EGTX, including a count of 48 and a latest link. Panel 8 mentions chosen reviews of EGTX on September 11 and 16. Panel 9 has a link to the ITC for BFRI. Panel 10 mentions that the ITC lifted a suspension on BFRI on September 1. The raw sha is 6765c17aa66a5a88e03a9d8235a15f264073c96992d15f4c653596e414a43372.